Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1970 2
1973 1
1975 1
1976 3
1977 2
1978 1
1979 3
1980 2
1981 3
1982 1
1983 3
1984 3
1985 5
1986 4
1987 5
1988 3
1989 4
1990 6
1991 4
1992 5
1993 2
1994 6
1995 8
1996 7
1997 4
1998 17
1999 13
2000 9
2001 8
2002 10
2003 16
2004 6
2005 5
2006 13
2007 5
2008 17
2009 9
2010 8
2011 9
2012 13
2013 16
2014 22
2015 31
2016 27
2017 21
2018 29
2019 15
2020 26
2021 30
2022 33
2023 27
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

488 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for goodwin weeks
Search for Woodwin Weeks instead (1 results)
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, Bird C, Blom RE, Brennan C, Brusch D, Burke L, Campbell-Coker K, Carhart-Harris R, Cattell J, Daniel A, DeBattista C, Dunlop BW, Eisen K, Feifel D, Forbes M, Haumann HM, Hellerstein DJ, Hoppe AI, Husain MI, Jelen LA, Kamphuis J, Kawasaki J, Kelly JR, Key RE, Kishon R, Knatz Peck S, Knight G, Koolen MHB, Lean M, Licht RW, Maples-Keller JL, Mars J, Marwood L, McElhiney MC, Miller TL, Mirow A, Mistry S, Mletzko-Crowe T, Modlin LN, Nielsen RE, Nielson EM, Offerhaus SR, O'Keane V, Páleníček T, Printz D, Rademaker MC, van Reemst A, Reinholdt F, Repantis D, Rucker J, Rudow S, Ruffell S, Rush AJ, Schoevers RA, Seynaeve M, Shao S, Soares JC, Somers M, Stansfield SC, Sterling D, Strockis A, Tsai J, Visser L, Wahba M, Williams S, Young AH, Ywema P, Zisook S, Malievskaia E. Goodwin GM, et al. N Engl J Med. 2022 Nov 3;387(18):1637-1648. doi: 10.1056/NEJMoa2206443. N Engl J Med. 2022. PMID: 36322843 Clinical Trial.
Secondary end points included response at week 3 (50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total score 10), and sustained response at 12 weeks (meeting response criteria at week 3 and all subsequent visits). ...In the 25-mg group, th …
Secondary end points included response at week 3 (50% decrease from baseline in the MADRS total score), remission at week 3 (MADRS total sco …
Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life.
Goodwin GM, Aaronson ST, Alvarez O, Atli M, Bennett JC, Croal M, DeBattista C, Dunlop BW, Feifel D, Hellerstein DJ, Husain MI, Kelly JR, Lennard-Jones MR, Licht RW, Marwood L, Mistry S, Páleníček T, Redjep O, Repantis D, Schoevers RA, Septimus B, Simmons HJ, Soares JC, Somers M, Stansfield SC, Stuart JR, Tadley HH, Thiara NK, Tsai J, Wahba M, Williams S, Winzer RI, Young AH, Young MB, Zisook S, Malievskaia E. Goodwin GM, et al. J Affect Disord. 2023 Apr 14;327:120-127. doi: 10.1016/j.jad.2023.01.108. Epub 2023 Feb 4. J Affect Disord. 2023. PMID: 36740140 Free article. Clinical Trial.
LIMITATIONS: Interpretation of this trial is limited by the absence of an active comparator and the possibility of functional unblinding in participants who received a low dose of psilocybin. CONCLUSIONS: Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, …
LIMITATIONS: Interpretation of this trial is limited by the absence of an active comparator and the possibility of functional unblinding in …
Minithoracotomy vs Conventional Sternotomy for Mitral Valve Repair: A Randomized Clinical Trial.
Akowuah EF, Maier RH, Hancock HC, Kharatikoopaei E, Vale L, Fernandez-Garcia C, Ogundimu E, Wagnild J, Mathias A, Walmsley Z, Howe N, Kasim A, Graham R, Murphy GJ, Zacharias J; UK Mini Mitral Trial Investigators. Akowuah EF, et al. JAMA. 2023 Jun 13;329(22):1957-1966. doi: 10.1001/jama.2023.7800. JAMA. 2023. PMID: 37314276 Free PMC article. Clinical Trial.
MAIN OUTCOMES AND MEASURES: The primary outcome was physical functioning and associated return to usual activities measured by change from baseline in the 36-Item Short Form Health Survey (SF-36) version 2 physical functioning scale 12 weeks after the index surgery, assess …
MAIN OUTCOMES AND MEASURES: The primary outcome was physical functioning and associated return to usual activities measured by change from b …
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial.
Catto JWF, Khetrapal P, Ricciardi F, Ambler G, Williams NR, Al-Hammouri T, Khan MS, Thurairaja R, Nair R, Feber A, Dixon S, Nathan S, Briggs T, Sridhar A, Ahmad I, Bhatt J, Charlesworth P, Blick C, Cumberbatch MG, Hussain SA, Kotwal S, Koupparis A, McGrath J, Noon AP, Rowe E, Vasdev N, Hanchanale V, Hagan D, Brew-Graves C, Kelly JD; iROC Study Team. Catto JWF, et al. JAMA. 2022 Jun 7;327(21):2092-2103. doi: 10.1001/jama.2022.7393. JAMA. 2022. PMID: 35569079 Free PMC article. Clinical Trial.
Participants undergoing open surgery reported worse quality of life vs robotic surgery at 5 weeks (difference in mean European Quality of Life 5-Dimension, 5-Level instrument scores, -0.07 [95% CI, -0.11 to -0.03]; P = .003) and greater disability at 5 weeks (differ …
Participants undergoing open surgery reported worse quality of life vs robotic surgery at 5 weeks (difference in mean European Qualit …
Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.
Goodwin GM, Croal M, Feifel D, Kelly JR, Marwood L, Mistry S, O'Keane V, Peck SK, Simmons H, Sisa C, Stansfield SC, Tsai J, Williams S, Malievskaia E. Goodwin GM, et al. Neuropsychopharmacology. 2023 Sep;48(10):1492-1499. doi: 10.1038/s41386-023-01648-7. Epub 2023 Jul 13. Neuropsychopharmacology. 2023. PMID: 37443386 Free PMC article. Clinical Trial.
Participants received a single 25 mg dose of psilocybin alongside psychological support and were followed-up for 3 weeks. The primary efficacy end point was change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score from Baseline at Week 3. ...
Participants received a single 25 mg dose of psilocybin alongside psychological support and were followed-up for 3 weeks. The primary …
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW. Meric-Bernstam F, et al. Lancet Oncol. 2022 Dec;23(12):1558-1570. doi: 10.1016/S1470-2045(22)00621-0. Epub 2022 Nov 16. Lancet Oncol. 2022. PMID: 36400106 Clinical Trial.
Part 1 followed a 3 + 3 dose-escalation design, including different intravenous doses (from 5 mg/kg to 30 mg/kg) and intervals (every 1, 2, or 3 weeks). The primary objective of part 2 was to evaluate the safety and tolerability of zanidatamab monotherapy in solid tumours. …
Part 1 followed a 3 + 3 dose-escalation design, including different intravenous doses (from 5 mg/kg to 30 mg/kg) and intervals (every 1, 2, …
Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis.
Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, Purgato M, Spineli LM, Goodwin GM, Geddes JR. Cipriani A, et al. Lancet. 2011 Oct 8;378(9799):1306-15. doi: 10.1016/S0140-6736(11)60873-8. Epub 2011 Aug 16. Lancet. 2011. PMID: 21851976 Review.
The main outcomes were the mean change on mania rating scales and the number of patients who dropped out of the allocated treatment at 3 weeks. Analysis was done by intention to treat. FINDINGS: Haloperidol (standardised mean difference [SMD] -0.56 [95% CI -0.69 to -0.43]) …
The main outcomes were the mean change on mania rating scales and the number of patients who dropped out of the allocated treatment at 3 …
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with score …
Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. Th …
Colorectal Endoscopic Stenting Trial (CReST) for obstructing left-sided colorectal cancer: randomized clinical trial.
CReST Collaborative Group. CReST Collaborative Group. Br J Surg. 2022 Oct 14;109(11):1073-1080. doi: 10.1093/bjs/znac141. Br J Surg. 2022. PMID: 35986684 Clinical Trial.
METHODS: Patients with left-sided colonic obstruction and radiological features of carcinoma were randomized to endoluminal stenting using a combined endoscopic/fluoroscopic technique followed by elective surgery 1-4 weeks later, or surgical decompression with or without t …
METHODS: Patients with left-sided colonic obstruction and radiological features of carcinoma were randomized to endoluminal stenting using a …
Standing frames for children with cerebral palsy: a mixed-methods feasibility study.
Goodwin J, Lecouturier J, Basu A, Colver A, Crombie S, Smith J, Howel D, McColl E, Parr JR, Kolehmainen N, Roberts A, Miller K, Cadwgan J. Goodwin J, et al. Health Technol Assess. 2018 Sep;22(50):1-232. doi: 10.3310/hta22500. Health Technol Assess. 2018. PMID: 30234480 Free PMC article. Clinical Trial.
The maximum amount of time most health professionals and parents would agree to suspend standing frame use would be 12 weeks. LIMITATIONS: Owing to the nature of recruitment, we could not calculate response rates or determine non-response bias. ...
The maximum amount of time most health professionals and parents would agree to suspend standing frame use would be 12 weeks. LIMITAT …
488 results